BioVaxys Technology Corp (CSE:BIOV) (FRA:5LB) (OTCQB:BVAXF), a clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics, announced on Thursday its acquisition of clinical study management company TAETSoftware Corp.

Based in Vancouver in British Columbia, Canada, TAETSoftware is engaged in the development and commercialisation of the Trial Adverse Events Tracker (TAET) technology platform, a proprietary software application designed to enable clinical study subjects to record and submit reports of adverse events and/or side effects to study sponsors in real time.

In exchange for all of the issued and outstanding shares of TAETCo, BioVaxys issued 24,500,000 common shares to TAETCo shareholders. An additional 2,500,000 common shares will become payable upon the successful testing of the beta version of the application.